The antibacterial textile industry is entering a concentrated standard transition. Public information indicates that Part 3 (shaking flask method) of the GB/T 20944 series has been revised and is pending release, while the review meeting for Part 2 (absorption method) was recently held in Zhejiang, with the revision task assigned in June 2025. This means the nearly 20-year-old antibacterial performance evaluation standards will soon be updated within the coming year.
Industry Background of the Revision
The three current standards—GB/T 20944.1-2007 (agar diffusion method), GB/T 20944.2-2007 (absorption method), and GB/T 20944.3-2008 (shaking flask method)—have provided the basic framework for market access and quality control of antibacterial textiles. Over the past two decades, antibacterial technologies have expanded from simple finishing agents to nanomaterials and bio-based antimicrobials, with applications extending from underwear and socks to medical textiles and home furnishings. Testing equipment has also become more precise and standardized, exposing limitations in old methods regarding strain selection, culture conditions, and result interpretation.
For purchasers, outdated standards mean that different laboratories may produce divergent antibacterial rate conclusions for the same fabric, directly affecting order acceptance and cross-border compliance. For manufacturers, lacking a unified technical language can lead to cutthroat competition based on low price and poor quality. Therefore, this revision is not a simple patch but a reconstruction of the entire evaluation logic.
Progress and Industry Transmission
Looking at the timeline, the revision task for Part 3 was assigned in June 2024 (plan number 20241952-T-608), and it has now completed revision, pending release, after which it will fully replace GB/T 20944.3-2008. The revision task for Part 2 was assigned in June 2025 (plan number 20251603-T-608), and the Zhejiang review meeting indicates initial approval of the draft by committee members. The drafting units include testing institutions, research institutes, brand companies, and new material enterprises, reflecting a balance between methodological rigor and industrial operability.
The revised standards are expected to introduce more realistic clauses on test strains, inoculum concentration, incubation time, and neutralization steps. For high-risk categories like sportswear and medical textiles, repeatability and reproducibility will be key priorities. This means companies must adjust internal quality control processes and possibly upgrade laboratory equipment to remain compliant under the new standards.
Impact on the Supply Chain
For upstream antibacterial agent suppliers, the new standards will indirectly screen out more stable and easily detectable technologies. Some additives that claim high efficacy but show high test variability may lose market share if they fail validation under new methods. For midstream fabric and garment companies, the revision directly affects the legality of product claims—antibacterial rates can no longer be self-declared but must be supported by reports generated under the new methods, or risk regulatory penalties.
For downstream buyers and brands, a more scientific evaluation system means more reliable quality assurance, helping reduce returns and complaints related to antibacterial performance disputes. Additionally, exporters need to monitor differences between the new Chinese standards and international methods (e.g., ISO 20743, AATCC 100) to avoid trade barriers caused by method switching.
Practical Recommendations
For Purchasers - Specify the latest version of GB/T 20944.2 or .3 in contracts and require supplier test reports based on new methods, avoiding acceptance using old standards. - Monitor transition periods and confirm with suppliers whether existing inventory needs retesting to prevent delivery delays due to standard changes.
For Foreign Trade Enterprises - Compare the revised standards with antibacterial testing requirements in destination markets, communicate with third-party labs on method equivalence, and conduct parallel tests if necessary. - Integrate standard revisions into product development plans, validating antibacterial performance using new methods during the design phase to reduce post-launch correction costs.
The window of standard revision is often a latent period for industry reshuffling. For companies that position antibacterial functionality as a core selling point, now is the best time to re-evaluate technical routes and quality control systems.